Bio-Rad Laboratories [BIO] vs Abbott Laboratories [ABT] Detailed Stock Comparison

Bio-Rad Laboratories Inc.

NYSE
Loading...

Abbott Laboratories

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 21 vital metrics comparison: Bio-Rad Laboratories Inc. wins in 11 metrics, Abbott Laboratories wins in 8 metrics, with 0 ties. Bio-Rad Laboratories Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bio-Rad Laboratories Inc. Abbott Laboratories Better
P/E Ratio (TTM) 10.98 25.97 Bio-Rad Laboratories Inc.
Price-to-Book Ratio 1.11 3.09 Bio-Rad Laboratories Inc.
Debt-to-Equity Ratio 18.58 26.79 Bio-Rad Laboratories Inc.
PEG Ratio -0.05 -1.41 Bio-Rad Laboratories Inc.
EV/EBITDA 18.75 13.74 Abbott Laboratories
Profit Margin (TTM) 29.42% 13.90% Bio-Rad Laboratories Inc.
Operating Margin (TTM) 8.87% 16.50% Abbott Laboratories
EBITDA Margin (TTM) 8.87% 16.50% Abbott Laboratories
Return on Equity 10.84% 12.36% Abbott Laboratories
Return on Assets (TTM) 1.67% 7.52% Abbott Laboratories
Free Cash Flow (TTM) $374.60M $7.40B Abbott Laboratories
Dividend Yield N/A 1.97% N/A
1-Year Return 26.01% -34.98% Bio-Rad Laboratories Inc.
Price-to-Sales Ratio (TTM) 3.20 3.57 Bio-Rad Laboratories Inc.
Enterprise Value $8.09B $166.96B Abbott Laboratories
EV/Revenue Ratio 3.13 3.70 Bio-Rad Laboratories Inc.
Gross Profit Margin (TTM) 49.80% N/A N/A
Revenue per Share (TTM) $95 $26 Bio-Rad Laboratories Inc.
Earnings per Share (Diluted) $27.85 $3.57 Bio-Rad Laboratories Inc.
Beta (Stock Volatility) 1.16 0.78 Abbott Laboratories
Short % of Float 0.00% 1.53% Bio-Rad Laboratories Inc.

Bio-Rad Laboratories Inc. vs Abbott Laboratories Stock Performance Analysis

Loading Price Chart...

BIO
ABT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bio-Rad Laboratories Inc.1.17%-0.70%16.87%10.73%-6.05%-5.24%
Abbott Laboratories0.56%-2.02%4.97%-19.35%-30.98%-28.60%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bio-Rad Laboratories Inc.26.01%-24.07%-54.09%102.91%143.91%328.31%
Abbott Laboratories-34.98%-16.97%-20.08%135.84%255.56%329.52%

Performance & Financial Health Analysis: Bio-Rad Laboratories Inc. vs Abbott Laboratories

MetricBIOABT
Market Information
Market Cap i$7.60B$160.70B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i239,62513,495,583
90 Day Avg. Volume i284,78512,934,461
Last Close$289.28$88.67
52 Week Range$222.80 - $343.12$81.97 - $139.06
% from 52W High-15.69%-36.24%
All-Time High$832.70 (Aug 30, 2021)$142.60 (Dec 27, 2021)
% from All-Time High-65.26%-37.82%
Growth Metrics
Quarterly Revenue Growth0.04%0.08%
Quarterly Earnings Growth0.04%-0.19%
Financial Health
Profit Margin (TTM) i0.29%0.14%
Operating Margin (TTM) i0.09%0.17%
Return on Equity (TTM) i0.11%0.12%
Debt to Equity (MRQ) i18.5826.79
Cash & Liquidity
Book Value per Share (MRQ)$276.16$30.02
Cash per Share (MRQ)$57.08$5.14
Operating Cash Flow (TTM) i$532.20M$10.80B
Levered Free Cash Flow (TTM) i$256.55M$13.77B
Dividends
Last 12-Month Dividend Yield iN/A1.97%
Last 12-Month Dividend iN/A$2.40

Valuation & Enterprise Metrics Analysis: Bio-Rad Laboratories Inc. vs Abbott Laboratories

MetricBIO (Apr 24, 2026)ABT (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i10.9825.97
Forward P/E i26.9415.29
PEG Ratio i-0.05-1.41
Price to Sales (TTM) i3.203.57
Price to Book (MRQ) i1.113.09
Market Capitalization
Market Capitalization i$7.60B$160.70B
Enterprise Value i$8.09B$166.96B
Enterprise Value Metrics
Enterprise to Revenue i3.133.70
Enterprise to EBITDA i18.7513.74
Risk & Other Metrics
Beta i1.160.78
Book Value per Share (MRQ) i$276.16$30.02

Financial Statements Comparison: Bio-Rad Laboratories Inc. vs Abbott Laboratories

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBIO (2025)ABT (2025)
Revenue/Sales i2.58B44.33B
Cost of Goods Sold i1.24B19.32B
COGS % of Revenue i48.1%43.6%
Gross Profit i1.34B25.01B
Gross Margin i51.9%56.4%
Research & Development i275.60M2.94B
Operating Income (EBIT) i218.60M8.05B
Operating Margin i8.5%18.2%
EBITDA i480.70M12.03B
EBITDA Margin i18.6%27.1%
Pre-Tax Income i995.50M8.47B
Pre-Tax Income % of Revenue i38.5%19.1%
Income Tax i235.60M1.94B
Income Tax % of Revenue i9.1%4.4%
Net Income (Profit) i759.90M6.52B
Profit Margin i29.4%14.7%

Balance Sheet & Liquidity Metrics

MetricBIO (2025)ABT (2025)
Cash & Equivalents i529.80M8.52B
Total Current Assets i2.91B26.00B
Total Current Assets % of Revenue i112.5%58.6%
Total Current Liabilities i517.00M16.50B
Total Current Liabilities % of Revenue i20.0%37.2%
Long-Term Debt i1.35B10.83B
Long-Term Debt % of Revenue i52.2%24.4%
Total Shareholders Equity i7.45B52.77B
Retained Earnings i8.18B49.78B
Retained Earnings % of Revenue i316.5%112.3%
Property, Plant & Equipment i1.49B17.57B

Cash Flow Statement Comparison

MetricBIO (2025)ABT (2025)
Operating Cash Flow i1.25B10.80B
Operating Cash Flow % of Revenue i48.4%24.4%
Capital Expenditures i-157.50M-2.17B
Free Cash Flow i374.60M7.40B
FCF Margin i14.5%16.7%
Debt Repayment i-500,000-1.50B
Common Stock Repurchase i-295.50M-893.00M

Short Interest & Institutional Ownership Analysis

MetricBIOABT
Shares Short i2623.83M
Short Ratio i0.001.93
Short % of Float i0.00%1.53%
Shares Outstanding i26.99M1.74B
Float Shares i21.13M1.73B
% Held by Insiders i16.20%0.54%
% Held by Institutions i91.50%82.23%
% Held by Public i-7.70%17.23%

Dividend Analysis & Yield Comparison: Bio-Rad Laboratories Inc. vs Abbott Laboratories

MetricBIOABT
Last 12-Month Dividend iN/A$2.40
Last 12-Month Dividend Yield iN/A1.97%
3-Year Avg Annual Dividend iN/A$2.24
3-Year Avg Dividend Yield iN/A0.50%
3-Year Total Dividends iN/A$6.72
Ex-Dividend DateN/AJan 15, 2026